psalexa
SearchBar Icon

Advancement in Technology to Support the Growth in RMS Therapeutics Pipeline

Published Date:   March 2018

RMS therapeutics pipeline currently exhibit a proliferating pipeline with 18 drug candidates, P&S Market Research.

RMS Therapeutics Pipeline in 2018

RMS is a rare and malignant type of tumor which can arise from skeletal muscles, tendons, or connective tissues. The pathophysiology of this type of cancer is still unknown, but when it arises from the skeletal muscles, it can spread to any part of the body. RMS majorly arises from skeletal muscles, but the reason behind this remains unknown. RMS is the most common soft tissue tumor that occurs during childhood and accounts for approximately half of all soft tissue sarcomas in this age group.

Insights on Pipeline Segments

According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug.

Browse report overview with detailed TOC on "Rhabdomyosarcoma (RMS) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis

RMS Therapeutics Pipeline is Witnessing Significant Growth due to Development of Combination Therapies

Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).

Combination therapies help to reduce frequency of dose administration, increase synergistic effect, and increase the potency of drugs for the treatment of RMS, thus driving the growth in pipeline.

Advancement in Technology to Support RMS Therapeutics Pipeline Growth

Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.

IPROTech platform is a versatile technology platform that can be applied to a wide variety of proteins. It is based on the repetition of cycles consisting of in-silico and in-vitro techniques. Some of the advantages of this technology include reduction of time and cost for manufacture of drugs, and the ability to render the drugs to reach intracellular targets.

Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.

RMS Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company